肝细胞癌转化治疗的现状与展望
收稿日期: 2022-01-17
网络出版日期: 2022-06-16
基金资助
国家重点基础研究发展规划（973计划）项目(2015CB554005);国家自然科学基金(81372655);国家自然科学基金(81472224);国家自然科学基金(81672326);上海市优秀学术/技术带头人计划(17XD140 1100)
Current status and perspectives of conversion therapy for hepatocellular carcinoma
孙惠川 . 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022 , 27(02) : 134 -138 . DOI: 10.16139/j.1007-9610.2022.02.010
| [1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
| [2] | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. |
| [3] | Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. |
| [4] | Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6. |
| [5] | Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival[J]. Surgery, 1970, 68(2):383-388. |
| [6] | Tang ZY, Liu KD, Bao YM, et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection[J]. Cancer, 1990, 65(2):211-215. |
| [7] | Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimoda-lity treatment[J]. Ann Surg, 1993, 217(2):149-154. |
| [8] | Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6):674-678. |
| [9] | Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma[J]. Ann Surg, 2004, 240(2):299-305. |
| [10] | Zhang Y, Huang G, Wang Y, et al. Is Salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? ten years of experience[J]. Oncologist, 2016, 21(12):1442-1449. |
| [11] | Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients[J]. World J Surg, 1995, 19(6):784-789. |
| [12] | 赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. 中国医学科学院学报, 2009, 31(4):503-505. |
| [13] | Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905. |
| [14] | Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable he-patocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7):977-990. |
| [15] | Zhu AX, Finn RS, Ikeda M, et al. A phase Ⅰb study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15_suppl):4519. |
| [16] | Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4):320-329. |
| [17] | Zhang W, Hu B, Han J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients[J]. Front Oncol, 2021, 11(4082):747950. |
| [18] | Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4):434-442. |
| [19] | Zhang J, Zhang X, Mu H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study[J]. Front Oncol, 2021, 11:729764. |
| [20] | Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma[J]. Ann Surg Oncol, 2021, 28(12)7663-7672. |
| [21] | Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9):891-903. |
| [22] | Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study[J]. J Hepatol, 2019, 70(5):893-903. |
| [23] | Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study[J]. Cancers (Basel), 2019, 11(8):1084. |
| [24] | Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity ma-thching score analysis[J]. Medicine (Baltimore), 2016, 95(11):e3015. |
| [25] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2):143-168. |
| [26] | 孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6):618-632. |
| [27] | Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970. |
| [28] | Kudo M, Ikeda M, Motomura K, et al. A phase Ⅰb study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(4_suppl):513. |
| [29] | Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319):1734-1739. |
| [30] | Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5):1164-1171. |
| [31] | Orlacchio A, Chegai F, Merolla S, et al. Downstaging di-sease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization[J]. World J Hepatol, 2015, 7(12):1694-1700. |
| [32] | Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478. |
| [33] | Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69. |
| [34] | Kamiyama T, Nakanishi K, Yokoo H, et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma[J]. Int J Clin Oncol, 2007, 12(5):363-368. |
| [35] | Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepato-cellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151. |
| [36] | Yarchoan M, Zhu Q, Durham JN, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2021, 39(3_suppl):335. |
| [37] | Zhang W, Hu B, Han J, et al. A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: a prospective, non-randomized, open-label cohort study[J]. Ann Oncol, 2020, 31:S1307. |
| [38] | Dhir M, Sasson AR. Surgical management of liver metastases from colorectal cancer[J]. J Oncol Pract, 2016, 12(1):33-39. |
/
| 〈 |
|
〉 |
